Events

CALIXAR team will be present at the virtual Biotech showcase, January 10–12, 2022 and January 17–19, 2022 to discuss partnering with other biopharmaceutical and life science actors and investors. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the BIOTECH SHOWCASE: The BIOTECH SHOWCASE is produced each year by Demy-Colton and EBD Group. This event allows companies to connect to thousands of peers from Startup, over Biotech and large Pharma. From early, mid to later stage. This 14th edition will be held online and will feature multiple tracks of curated presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. For more information: BIOTECH SHOWCASE  

CALIXAR team will be present at the online BioFIT event, from December 07 to 09, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to pharmaceutical companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BioFIT: With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs, and emerging biotech companies. Together with big pharma, biotech, and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed, and Series A investment in Life Sciences. For more information and meet us: BioFIT

CALIXAR team will be present at the online i-GPCRnet from November 30th to December 03rd, 2021 to discuss different topics relating to Membrane Proteins and more specifically on GPCRs. G protein-coupled receptors (GPCRs) are among the most important protein families in sensing environmental changes at the cellular level providing them adequate response and adaptation. Their potential as drug targets has been recognized with 30-40% of currently marketed drugs targeting GPCRs. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …) and is constantly improving to deliver the most pure and stable targets to biotechnology and pharmaceutical companies. During the session “Up and coming technologies to targets GPCRs”, Dr. Vincent CORVEST, Senior Scientist and Business Manager at CALIXAR will give a flash presentation on the know-how of CALIXAR on Membrane Proteins and works conducted on GPCRs. About i-GPCRnet: The ambition of the i-GPCRnet is to tackle the largely unexplored question of the impact of the microenvironments on GPCR function and how perturbation of this microenvironment impacts on common diseases such as cancer, metabolic and neurodegenerative diseases as well as their therapies. A better understanding of the GPCR microenvironment holds the promise of unprecedented therapeutic opportunities in terms of tissue specificity and specific pharmacological targeting that will eventually lead to the design of innovative and tailored drugs for precision medicine. To reach this goal the i-GPCRnet consortium will bring together chemists, biophysicists, bioinformaticians, mathematicians, systems and cellular biologists and pharmacologists. For more information and meet us: i-GPCRnet  

CALIXAR team will be on-site workshop at the second APPICOM plenary, from November 15 to 18, 2021 to discuss different topics relating to Membrane Proteins. Membrane therapeutic targets (GPCRs, ion channels, transporters, …) are essential as templates in the development of drug candidates, both in small molecule screening and in the manufacture of therapeutic antibodies, or as antigens in the development of new vaccines. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …) and is constantly improving to deliver the most pure and stable targets to biotechnology and pharmaceutical companies. Chem2stab, the joint laboratory of CALIXAR and the university of Avignon (France) since 2015 will also participate in this event. Grégory Durand and Valentin Monjal, chemists from Chem2Stab will talk about new chemical tools (polymers and sugar-based amphiphilic molecules) for the extraction and stabilization of therapeutic targets without denaturing them. About Appicom: The Group APPICOM gathers 91 research teams coming from 49 research institutes, in France and abroad. APPICOM regroups teams interested in membrane proteins, from biochemical and structural studies to pharmacology and dynamic simulations, and cellular and physiological investigations. APPICOM was created on January 1st, 2020 by the CNRS (French National Research Center), with support from all associated labs Institutional bodies: Universities, INSERM, INRA and CEA. For more information and meet us: APPICOM

CALIXAR team will be present at the online Bio Europe event, from October 25 to 28, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About Bio Europe: The international BIO-Europe® 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs. BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. For more information and meet us: Bio Europe

CALIXAR team will be present at the online Bio Japan event, from October 13 to 15, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About Bio Japan: This event is constituted by three exhibitions – The world’s oldest biotechnology exhibition “BioJapan” (1986), “Regenerative Medicine JAPAN” (2016), aiming at accelerating and industrializing R&D in the field of regenerative medicine including iPS cells, and “health TECH JAPAN”(2020), provides fusion of digital technology and life science. The goal is to provide new value through business partnering of industry, academia, and government which is not limited to Japan, but also from overseas. With the addition of Digital & In-Person partnering program started from 2020, global innovation through this partnering event never stops at all. For more information and meet us: Bio Japan / CALIXAR

CALIXAR team will be present at the online BioPharm America event, from September 20 to 23, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BioPharm America: BioPharm America™ Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions. It brings dealmakers from the life science ecosystem together to engage and reduce the enormous task of drug development. For more information and meet us: BioPharm America  

CALIXAR team will be present at the online European Biotech ＆ Pharma Partnering Conference, from September 27 to 30, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About European Biotech ＆ Pharma Virtual Partnering Conference: The European Biotech ＆ Pharma Virtual Partnering Conference 2021 offers business contacts to industry professionals who are looking for potential partners to ensure sustainable business development and growth. The event is co-organized by the Osaka Prefectural Government, the EU-Japan Centre for Industrial Cooperation and it will be supported by the Enterprise Europe Network and various Bioclusters from Japan and Europe.  

CALIXAR team will be present at the online BIO Asia – Taiwan event, from July 21 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO Asia – Taiwan event Jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO) the BIO Asia – Taiwan International Conference and Exhibition was held for the first time in 2019.  This year BIO Asia – Taiwan 2021 (online), brings together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to explore business opportunities with Taiwan’s emerging biotech sector with a unique format of online and live settings. For more information and meet us: BIO Asia – Taiwan

CALIXAR team will be present at the online 9th Antibody Industrial Symposium 2021, from June 22 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About 9th Antibody Industrial Symposium The 9th Antibody Industrial Symposium is an international congress jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013. The AIS2021 is the ideal conference for scientists, industrials, physicians and policymakers to exchange about therapeutic antibodies and more! The Scientific committee has set up an exciting program, with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies. For more information and meet us: 9th Antibody Industrial Symposium

CALIXAR team will be present at the online BIO KOREA International Convention event, from June 9 to 21, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO KOREA International Convention BIO KOREA has been held every year since 2006 and serving as a business platform for international bio companies. This 15th-year event brings together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, through exhibitions, business forums (partnering), and conferences. BIO KOREA has been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology. For more information and meet us: BIO KOREA International Convention

CALIXAR team will attend at the online Redefining Early Stage Investments (RESI) event, from June 8 to 10, 2021 to present its new licensing business model and to develop its pipeline of native targets of pharmaceutical interest. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the Redefining Early Stage Investments (RESI) The Redefining Early Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. The RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. The RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). For more information and meet us: Redefining Early Stage Investments (RESI)

CALIXAR team will be present at the online Festival of Biologics USA, from March 29 to April 01, 2021 to meet you and discuss about commercial and scientific issues linked to our activities. CALIXAR is a biotech company specialized in the isolation of native membrane therapeutic targets and antigens. This digital event will be a great opportunity to present CALIXAR’s proprietary technologies and know-how to collaborate with academia and industries in the development of innovative drugs and antibodies. About the Festival of Biologics USA: The Festival of Biologics USA is the meeting place for the life science community to bridge the gap between academia and industry. With three events in one (the Americas Antibody Congress, and the World Immunotherapy Congress), this Festival encourages conversation across the entire industry, to inspire change, champion innovation, and address complex challenges that the biologics industry is facing. For more information and meet us: Festival of Biologics USA

CALIXAR team will participate at the 4th Congress of Immunotherapies & Innovations for Infectious Diseases to meet partners working on this thematic and exchange about strategies and scientific issues tied up on its activities.

CALIXAR team will be present at BIO Europe Digital, the October 26-29, 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO JAPAN 2020 event online, (October 14-16th, 2020) to meet you and exchange about commercial and scientific opportunities tied up on our activities.

CALIXAR team will be present at Biotech & Pharma Virtual Partnering Conference, the 28 to 30 September 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO Digital, the 8-12 June 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will attend at Virtual Partnering Event against Covid-19 on 4 to 6 May 2020.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will be present at BIO-EUROPE SPRING event at Paris, the 23-25 March 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR to sponsor the 8th annual meeting of GDR3545-GPCR in Montpellier – France.

CALIXAR selected speaker at the EMBO Workshop: Tools for Structural Biology of Membrane Proteins in Hamburg.

Case study of Potassium chloride co-transporter KCC2;

CALIXAR to attend the 17th Annual Discovery on Target Summit in Boston

CALIXAR as invited speaker at the Immuno-technologies Day in Paris.

CALIXAR to attend the 7th Antibody Industrial Symposium in Tours.

CALIXAR to present at the 14th Annual Drug Discovery Chemistry Conference in San Diego.